DK3183272T3 - Asymmetriske multispecifikke antistoffer - Google Patents
Asymmetriske multispecifikke antistoffer Download PDFInfo
- Publication number
- DK3183272T3 DK3183272T3 DK15751030.6T DK15751030T DK3183272T3 DK 3183272 T3 DK3183272 T3 DK 3183272T3 DK 15751030 T DK15751030 T DK 15751030T DK 3183272 T3 DK3183272 T3 DK 3183272T3
- Authority
- DK
- Denmark
- Prior art keywords
- asymmetric
- multispecific antibodies
- multispecific
- antibodies
- asymmetric multispecific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1414823.3A GB201414823D0 (en) | 2014-08-20 | 2014-08-20 | Multispecific antibodies |
PCT/EP2015/069186 WO2016026943A1 (en) | 2014-08-20 | 2015-08-20 | Asymmetric multispecific antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3183272T3 true DK3183272T3 (da) | 2022-01-03 |
Family
ID=51662727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15751030.6T DK3183272T3 (da) | 2014-08-20 | 2015-08-20 | Asymmetriske multispecifikke antistoffer |
Country Status (5)
Country | Link |
---|---|
US (2) | US10487156B2 (da) |
EP (1) | EP3183272B1 (da) |
DK (1) | DK3183272T3 (da) |
GB (1) | GB201414823D0 (da) |
WO (1) | WO2016026943A1 (da) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9914785B2 (en) | 2012-11-28 | 2018-03-13 | Zymeworks Inc. | Engineered immunoglobulin heavy chain-light chain pairs and uses thereof |
BR112016027888A2 (pt) | 2014-05-28 | 2017-10-24 | Zymeworks Inc | construto de polipeptídeo de ligação ao antígeno isolado, polinucleotídeo isolado ou um conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do construto, método para tratar um sujeito com uma doença ou distúrbio, método para obter um construto, método para preparar um construto, meio de armazenamento legível por computador, método para produzir um construto de polipeptídeo de ligação com antígeno bi-específico e método para preparar um construto de polipeptídeo de ligação com antígeno isolado |
AU2016334063B2 (en) | 2015-10-08 | 2023-05-25 | Zymeworks Bc Inc. | Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof |
WO2017165464A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
MA45602A (fr) | 2016-07-08 | 2019-05-15 | Staten Biotechnology B V | Anticorps anti-apoc3 et leurs méthodes d'utilisation |
EP3559029A2 (en) | 2016-12-23 | 2019-10-30 | Bristol-Myers Squibb Company | Design of therapeutic immunoglobulin g4 for improved bioanalytical and bioprocessing properties |
US20200291089A1 (en) | 2017-02-16 | 2020-09-17 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
KR102694225B1 (ko) * | 2017-03-27 | 2024-08-09 | 바이오뮤넥스 파마슈티컬스 | 안정적인 다중특이적 항체 |
CN110506056A (zh) | 2017-04-21 | 2019-11-26 | 斯塔滕生物技术有限公司 | 抗apoc3抗体和其使用方法 |
JP2020522254A (ja) | 2017-05-31 | 2020-07-30 | エルスター セラピューティクス, インコーポレイテッド | 骨髄増殖性白血病(mpl)タンパク質に結合する多特異性分子およびその使用 |
UY37758A (es) | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
WO2019087115A1 (en) | 2017-10-31 | 2019-05-09 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
US20210009711A1 (en) | 2018-03-14 | 2021-01-14 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
JP7133043B2 (ja) | 2018-06-09 | 2022-09-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dll3-cd3二重特異性抗体 |
DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
SG11202106393SA (en) | 2018-12-24 | 2021-07-29 | Sanofi Sa | Pseudofab-based multispecific binding proteins |
CA3130628A1 (en) | 2019-02-21 | 2020-08-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
CA3131014A1 (en) | 2019-02-21 | 2020-08-27 | Andreas Loew | Anti-tcr antibody molecules and uses thereof |
GB2597851B (en) | 2019-02-21 | 2024-05-29 | Marengo Therapeutics Inc | Antibody molecules that bind to NKP30 and uses thereof |
AU2020226893A1 (en) | 2019-02-21 | 2021-09-23 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
GB2599229B (en) | 2019-02-21 | 2024-04-24 | Marengo Therapeutics Inc | Multifunctional molecules that bind to calreticulin and uses thereof |
WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
WO2021217085A1 (en) | 2020-04-24 | 2021-10-28 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
AU2021333779A1 (en) | 2020-08-26 | 2023-04-13 | Marengo Therapeutics, Inc. | Methods of detecting TRBC1 or TRBC2 |
CN116917316A (zh) | 2020-08-26 | 2023-10-20 | 马伦戈治疗公司 | 与NKp30结合的抗体分子及其用途 |
EP4204450A2 (en) | 2020-08-26 | 2023-07-05 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
JP2024515591A (ja) | 2021-04-08 | 2024-04-10 | マレンゴ・セラピューティクス,インコーポレーテッド | Tcrに結合する多機能性分子およびその使用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1928506A4 (en) | 2005-08-19 | 2009-10-21 | Abbott Lab | IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF |
WO2007147901A1 (en) * | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
PL2606064T3 (pl) | 2010-08-16 | 2015-07-31 | Novimmune Sa | Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał |
KR20200052383A (ko) * | 2011-03-25 | 2020-05-14 | 아이크노스 사이언스 에스. 아. | 헤테로 이량체 면역글로불린 |
DK2768857T3 (da) * | 2011-10-19 | 2020-02-03 | Novimmune Sa | Fremgangsmåder til oprensning af antistoffer |
GB2504139B (en) * | 2012-07-20 | 2014-12-31 | Argen X Bv | Antibodies to highly conserved targets produced by the immunisation of Camelidae species |
GB201203071D0 (en) * | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
JP6273219B2 (ja) * | 2012-03-13 | 2018-01-31 | ノビミューン エスアー | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
JP2016509014A (ja) * | 2013-02-08 | 2016-03-24 | ステムセントリックス, インコーポレイテッド | 新規の多特異的構成物 |
-
2014
- 2014-08-20 GB GBGB1414823.3A patent/GB201414823D0/en not_active Ceased
-
2015
- 2015-08-20 DK DK15751030.6T patent/DK3183272T3/da active
- 2015-08-20 US US15/503,602 patent/US10487156B2/en active Active
- 2015-08-20 EP EP15751030.6A patent/EP3183272B1/en active Active
- 2015-08-20 WO PCT/EP2015/069186 patent/WO2016026943A1/en active Application Filing
-
2019
- 2019-10-11 US US16/599,883 patent/US11649295B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20170342166A1 (en) | 2017-11-30 |
WO2016026943A1 (en) | 2016-02-25 |
EP3183272A1 (en) | 2017-06-28 |
US10487156B2 (en) | 2019-11-26 |
US20200157248A1 (en) | 2020-05-21 |
GB201414823D0 (en) | 2014-10-01 |
EP3183272B1 (en) | 2021-11-03 |
US11649295B2 (en) | 2023-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3183272T3 (da) | Asymmetriske multispecifikke antistoffer | |
DK3126395T3 (da) | Multispecifikke antistoffer | |
DK3556777T3 (da) | Multispecifikke antistofkonstrukter | |
DK3344654T3 (da) | Anti-lag-3-antistoffer | |
DK3183051T3 (da) | Væske-til-luftmembranenergivekslere | |
DK3134402T3 (da) | 4-amino-imidazoquinolinforbindelser | |
DK3211743T3 (da) | Ø-til-netværk-omskiftningsfremgangsmåde | |
DK3560954T3 (da) | Modificeret j-kæde | |
DK3222714T3 (da) | Phytasemutanter | |
DK3157559T3 (da) | Anti-axl-antistoffer | |
DK3350218T3 (da) | Polyomavirus-neutraliserende antistoffer | |
DK3119396T3 (da) | Muscarinreceptoragonister | |
DK3006072T3 (da) | Karadgang | |
DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
DK3215530T3 (da) | Forbedrede il-6 antistoffer | |
DE112015001664A5 (de) | Betätigungsaktuator | |
DK3183340T3 (da) | Termolabile exonukleaser | |
DK3154703T3 (da) | Fuldkappe-snekkecentrifuge | |
DK3154689T3 (da) | Komplekser | |
DK3110439T3 (da) | Pcsk9-vacciner | |
DE112015005041A5 (de) | Gargerätevorrichtung | |
DK3154945T3 (da) | Komplekser | |
FI20145153A (fi) | Aurinkolämpöabsorberielementti | |
DE102014000623A8 (de) | Halbhohlnietelement | |
DK3009858T3 (da) | Skyradar |